Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: A multicentre retrospective study on 80 patients

Rheumatology (United Kingdom)

Volumn 53, Issue 3, 2014, Pages 532-539

  Charles, Pierre ^a,b   Néel, Antoine ^c   Tieulié, Nathalie ^d   Hot, Arnaud ^e   Pugnet, Gregory ^f   Decaux, Olivier ^g   Marie, Isabelle ^h   Khellaf, Mehdi ⁱ   Kahn, Jean Emmanuel ^j   Karras, Alexandre ^k   Ziza, Jean Marc ^l   Deligny, Christophe ^m   Tchérakian, Colas ^j   Guillevin, Loïc ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT MUTUALISTE MONTSOURIS   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f CHU PURPAN   (France)

^g RENNES UNIVERSITY HOSPITAL   (France)

^h ROUEN UNIVERSITY HOSPITAL   (France)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j FOCH HOSPITAL   (France)

^k HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^l GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^m CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

more..

Author keywords

ANCA associated vasculitis; Anti CD20; Biologics; Eosinophilic granulomatosis with polyangiitis; Granulomatosis with polyangiitis; Microscopic polyangiitis; Rituximab

Indexed keywords

ANCA-ASSOCIATED VASCULITIS; ANTI-CD20; BIOLOGICS; EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS; GRANULOMATOSIS WITH POLYANGIITIS; MICROSCOPIC POLYANGIITIS; RITUXIMAB;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; BACTERIAL INFECTIONS; DISEASE MANAGEMENT; FEMALE; FRANCE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84894316831     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket381     Document Type: Article

References (20)

1. Specks U, Fervenza FC, McDonald TJ et al. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44:2836-40.
2. Jones RB, Ferraro AJ, Chaudhry AN et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009;60:2156-68.
3. Holle JU, Dubrau C, Herlyn K et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 2012;71:327-33.
4. Cartin-Ceba R, Golbin JM, Keogh KA et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 2012;64:3770-8.
5. Keogh KA, Wylam ME, Stone JH et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 2005;52:262-8.
6. Taylor SRJ, Salama AD, Joshi L et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009;60:1540-7.
7. Aries PM, Hellmich B, Voswinkel J et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006;65:853-8.
8. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
9. Jones RB, Tervaert JWC, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
10. Boren EJ, Cheema GS, Naguwa SM et al. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 2008;30:90-8.
11. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
12. Luqmani RA, Bacon PA, Moots RJ et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994;87:671-8.
13. Luqmani RA. Assessing disease activity in the systemic vasculitides. Curr Opin Rheumatol 2002;14:23-8.
14. De Groot K, Gross WL, Herlyn K et al. Development and validation of a Disease Extent Index for Wegener's granulomatosis. Clin Nephrol 2001;55:31-8.
15. Exley AR, Bacon PA, Luqmani RA et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80.
16. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
17. Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17.
18. Smith RM, Jones RB, Guerry M-J et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:3760-9.
19. Buch MH, Smolen JS, Betteridge N et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909-20.
20. Guerry MJ, Brogan P, Bruce IN et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology 2012;51:634-43.